Issue: 340B

Study Confirms 340B Affects Small Share of US Drug Market

A new report by independent researchers refutes claims by the pharmaceutical industry that the 340B drug pricing program is so large it forces manufacturers to raise their prices. Publication of the new report comes as Congress and the Trump administration are debating policies to reduce the scope of the 340B program, which, for the past 25 years, has helped provide low-cost medications and better health outcomes for millions of Americans and the non-profit hospitals and clinics.

Learn More